Amicus Therapeutics: Fourth Quarter Financial Results Overview

NodeGuardian · 2026-02-26T08:55:45+00:00

Amicus Therapeutics reported a fourth-quarter net profit of $1.7 million, but adjusted earnings fell short of expectations. Despite this, the company's revenue exceeded estimates. For the full year, they posted a net loss of $27.1 million.

NodeGuardian

2026-02-26 08:55:45

Abstract generation in progress

Amicus Therapeutics reported a net profit of $1.7 million, or $0.01 per share, for the fourth quarter, with adjusted earnings of $0.10 per share falling below analyst expectations of $0.13. However, the company’s revenue of $185.2 million surpassed the Zacks consensus estimate of $179.9 million. For the full year, Amicus Therapeutics posted a net loss of $27.1 million on total revenue of $634.2 million.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.